Health Care/Hospital
WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment
SHANGHAI, March 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for outstanding performance in the 2023 Climate Change Assessment conducted by the global environ...
2024-03-05 21:00
1679
IRBM Expands Global Reach in Drug Discovery with New Boston Office
Strategic Growth and Increased Visibility Set to Enhance IRBM's Leadership Position ROME, March 5, 2024 /PRNewswire/ -- IRBM, an integrated drug discovery Contract Research Organization (CRO), announces its global expansion with a new office inBoston, Massachusetts, a cornerstone for biotechnolo...
2024-03-05 20:24
1966
One Million Global Healthcare Seekers Embrace MedicalTourism.com: Medical Tourism Magazine Leads the Way
WEST PALM BEACH, Fla., March 5, 2024 /PRNewswire/ -- Launched in 2023 by The Medical Tourism Association, DarwinAI (Artificial Intelligence) is an AI-enabled marketing technology revolutionizing the medical tourism landscape. Darwin AI uses powerful AI-enabled algorithms to drive brand awareness,...
2024-03-05 16:00
1687
Cetaphil® Strengthens Ties with the Malaysian Community through Collaborative Partnership with Mira Filzah as the New Face of the Brand in 2024
KUALA LUMPUR, Malaysia, March 5, 2024 /PRNewswire/ -- Cetaphil®, the No.1 dermatological skincare brand inMalaysia, proudly announces a significant partnership in anticipating of the holy month of Ramadan. The brand is thrilled to unveil the newest face of Cetaphil® for 2024, the versatile Malays...
2024-03-05 14:58
1762
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2024-03-05 13:35
2445
First Patient Treated in Phase 2 GvHD Trial
MELBOURNE, Australia, March 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial ofCYP-001...
2024-03-05 10:08
1796
Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform
MELBOURNE, Australia, March 5, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manuf...
2024-03-05 07:01
1727
Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
TAIPEI, March 4, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (6838.TWO) and AimMax Therapeutics (United States) announced today that the U.S. Food and Drug Administration (FDA) has approved clobetasol propionate ophthalmic suspension 0.05% (APP13007), for the treatment of post-opera...
2024-03-05 06:55
1583
ACROBiosystems Launches New Initiative to Support Cell and Gene Manufacturers
NEWARK, Calif., March 4, 2024 /PRNewswire/ -- ACROBiosystems, one of the leading providers of innovative tools and solutions used from discovery to the clinic, has announced a new corporate initiative to supportex vivo cell manufacturing and manufacturers of innovative cell and gene therapies. I...
2024-03-04 22:00
1372
Optimum Nutrition Launches New Global Marketing Campaign "Unlock More You"
The campaign taps into the universal human desire to unlock more within ourselves, regardless of athletic ability or achievement DUBLIN, March 4, 2024 /PRNewswire/ -- Optimum Nutrition, the world's #1 sports nutrition brand1 from Glanbia Performance Nutrition (GPN), today releases its new global...
2024-03-04 22:00
2845
Cyient Partners with MassMedic to Accelerate MedTech Innovation
HYDERABAD, India, March 4, 2024 /PRNewswire/ -- Cyient, a global Intelligent Engineering and Technology Solutions company, is thrilled to announce its membership with the Massachusetts Medical Device Industry Council (MassMedic), the largest regional MedTech association inthe United States. This ...
2024-03-04 22:00
1409
Neurophet introduces AI-powered brain imaging analysis technology at AD/PD 2024
- Showcases brain imaging analysis technology with key products Neurophet AQUA and Neurophet SCALE PET - Aims to commercialize ARIA analysis and amyloid-positive prediction technology SEOUL, South Korea, March 4, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company f...
2024-03-04 22:00
1583
KCI, a subsidiary of Samyang Group, won 'Platinum Medal' in EcoVadis ESG Rating, Ranked in the Top 1% worldwide
* Evaluated firstly as a L'Oreal partner in 2013 and achieved the highest rating in 11 years * Efforts to establish an ESG committee, reinforce labor and human rights management, and improve management of partners SEOUL, South Korea, March 4, 2024 /PRNewswire/ -- Samyang Group announced that ...
2024-03-04 21:30
1492
Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development
SHANGHAI, March 4, 2024 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited consolidated management accounts for the year ended31 December, 2023 (the "Reporting Period") and the information currently available to the Board,it...
2024-03-04 21:19
2359
Milliken & Company Recognized Among the 2024 World's Most Ethical Companies®
SPARTANBURG, S.C., March 4, 2024 /PRNewswire/ -- Diversified global manufacturer Milliken & Company is proud to be included on the 2024 World's Most Ethical Companies list curated by Ethisphere, a leader in defining and advancing the standards of ethical business practices. This annual recognition...
2024-03-04 21:00
1539
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
SHANGHAI, March 4, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, today announced the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has officially approved the YOLT-2...
2024-03-04 20:00
747
Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management
MANCHESTER, England, March 4, 2024 /PRNewswire/ -- Phagenesis, a pioneering UK company which has developed a revolutionary neurostimulation system to treat swallowing dysfunction, has closed a$42M Series D financing all equity investment round. The combined European andUnited States investment sy...
2024-03-04 20:00
1276
Hybribio Calls for Raising International HPV Awareness
GUANGZHOU, China, March 4, 2024 /PRNewswire/ -- March 4th 2024 marks the 7th International HPV Awareness Day, a global campaign proposed by the International Papillomavirus Society (IPVS) since 2018. This year, the theme is One Less Worry. On this special day, Hybribio (300639.SZ) calls for raisi...
2024-03-04 18:47
1866
Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting
JINAN, China, March 4, 2024 /PRNewswire/ -- The European Society of Gynecological Oncology (ESGO) 2024 Conference has recently made selected abstracts available online. The abstract (abstract # 251) that details results from the Phase II clinical trial (DUBHE-C-206) evaluating the efficacy and s...
2024-03-04 16:53
1815
Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum's Disease
* CBL-514 is the first and only drug to receive both Orphan Drug Designation and Fast Track designation for Dercum's disease treatment. NEW TAIPEI CITY, March 4, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the U.S. Food and Drug Administration (FDA) granted Orphan D...
2024-03-04 16:22
1612
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9273
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7751